Current Imaging Mandate for Newly Diagnosed Cervical Cancer
For all newly diagnosed cervical cancer patients with stage IB2 disease or greater, PET/CT from skull base to mid-thigh is mandated at initial staging according to NCCN guidelines, given a 13.7% rate of unsuspected distant metastatic disease in this population. 1
Imaging Algorithm by Disease Extent
Local Staging (All Patients)
MRI pelvis without and with IV contrast is the primary modality for initial local staging to assess:
- Tumor size and location
- Depth of stromal invasion
- Parametrial invasion (which precludes surgery)
- Vaginal extension
- Bladder or rectal wall involvement 1
Systemic Staging (Stage IB2 or Greater)
PET/CT is the current modality of choice for nodal and distant metastatic disease assessment, demonstrating superior performance with:
- Sensitivity: 75% and specificity: 98% for lymph node assessment (compared to 56%/93% for MRI and 58%/92% for CT)
- Overall sensitivity 54.8%, specificity 97.7%, and NPV 93.1% for distant metastases
- Detection of occult metastases in up to 38% of patients with stage IB2 or greater disease 1
Alternative approach if PET/CT unavailable:
- CT chest with IV contrast (mandatory for lung metastases)
- CT abdomen and pelvis with IV contrast
- These are complementary procedures ordered simultaneously 1
Early Stage Disease (IA1-IB1 ≤2cm)
For tumors ≤4 cm confined to cervix on pelvic MRI with no gross pelvic nodal involvement:
- Pelvic MRI alone is sufficient
- Additional extra-pelvic imaging has 100% false-positive rate with no clinical utility
- Leads to unnecessary interventions without detecting metastases 2
Key Implementation Points
The 2018 FIGO staging update now incorporates imaging findings, creating new stages:
- IIIC1: Radiologically or pathologically confirmed pelvic lymph node metastases
- IIIC2: Para-aortic lymph node metastases 1, 3, 4
Common pitfall to avoid: Ordering extensive imaging for early-stage disease (≤IB1 with tumor ≤4cm on MRI) results in false-positive findings requiring unnecessary biopsies and interventions without identifying true metastases 2.
Contrast administration: IV contrast is strongly preferred for all CT and MRI examinations, as noncontrast studies provide poor soft tissue characterization and decreased sensitivity for small lesions 1.
Most common metastatic sites to evaluate: lung, peritoneum, supraclavicular lymph nodes, liver, and bone 1.
The evidence strongly supports this tiered approach, with the 2024 ACR Appropriateness Criteria 1 and NCCN guidelines 5, 6 providing the highest-quality recommendations that prioritize detection of metastatic disease to guide appropriate treatment selection and improve survival outcomes.